Brief: Maxcyte Signs Strategic Platform License
16/09/2024 07:37
Sept 16 (Reuters) - MaxCyte Inc MXCT.O :
* SIGNING OF STRATEGIC PLATFORM LICENSE
* SIGNS STRATEGIC LICENSE WITH KAMAU THERAPEUTICS
Source text for Eikon: ID:nRSP2334Ea
Further company coverage: MXCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte Q1 revenue falls
Brief: Maxcyte Appoints Parmeet Ahuja As Chief Financial Officer
Brief: Maxcyte Announces Preliminary Unaudited Fourth Quarter And Full Year 2025 Financial Results
MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments
Brief: MaxCyte Announces Planned CFO Transition In 2026